Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02006576 · ClinicalTrials.gov registry record · Phase 2

Prostaglandin Inhibition for Emphysema

A Phase 2 study of Emphysema, sponsored by University of Nebraska.

Completed
Registry status
Phase 2
Development phase
118
Enrollment target
5
Study locations

NCT02006576: Completed Phase 2 study of Emphysema, sponsored by University of Nebraska.

NCT02006576 is a Phase 2 study of Emphysema that has completed, run by University of Nebraska. The registered enrollment target is 118 participants, below the 3,799-participant average among 25 other Emphysema trials with a reported enrollment target (97% lower). The trial reports 5 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02006576, a Phase 2 study of Emphysema, has completed, sponsored by University of Nebraska.

COMPLETED
Registry status
Phase 2
Development phase
118 participants
Enrollment target
5
Study locations

Study Summary

The Prostaglandin Inhibition for Emphysema (PIE) study will determine if a currently available therapy, ibuprofen 600 mg three times daily, can block PGE production in the lower respiratory tract and if this results in improvement in measures of lung repair function.

Primary Outcome

PGE will be measured by HPLC in alveolar fluids obtained at randomization (week 0) and again 12 weeks after randomization on emphysema subjects taking placebo and emphysema subjects taking ibuprofen to compare control group versus treatment group.

Conditions Studied

Interventions

  • DRUG 600 mg ibuprofen three times daily for 48 weeks
  • OTHER Placebo three times daily

Study Locations (5)

Alabama

  • University of Alabama at Birmingham - Birmingham

California

  • Harbor-UCLA Medical Center - Torrance

Colorado

  • National Jewish Health - Denver

Nebraska

  • Univerisity of Nebraska Medical Center - Omaha

Pennsylvania

  • Temple University - Philadelphia

Trial Details

FieldValue
Enrollment Target 118 participants
Start Date 2014-01-01
Est. Completion 2018-03-31
Phase Phase 2
University of Nebraska

407 total trials

What the finished NCT02006576 record still lists

NCT02006576 is an interventional study that assigns participants to a tested intervention. The registered 118 participants enrollment target is mid-sized for trials with a published cap, below the 3,799-participant average among 25 other Emphysema trials with a reported enrollment target (97% lower).

The record links to 1 condition, with Emphysema appearing as the primary indexed condition, and to 2 interventions - of which 600 mg ibuprofen three times daily for 48 weeks is the first listed.

NCT02006576 lists 5 locations in 5 states (Alabama, California, Colorado).

Frequently Asked Questions

What is clinical trial NCT02006576 about?

NCT02006576 is a clinical study titled "Prostaglandin Inhibition for Emphysema". The Prostaglandin Inhibition for Emphysema (PIE) study will determine if a currently available therapy, ibuprofen 600 mg three times daily, can block PGE production in the lower respiratory tract and if this results in improvement in measures of lung repair function.

What is the current status of trial NCT02006576?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 118 participants. The study started on 2014-01-01. Estimated completion is 2018-03-31.

What conditions does trial NCT02006576 study?

This clinical trial studies the following conditions: Emphysema.

What interventions are being tested in trial NCT02006576?

The interventions under investigation include: 600 mg ibuprofen three times daily for 48 weeks (DRUG), Placebo three times daily (OTHER).

Who is sponsoring clinical trial NCT02006576?

This trial is sponsored by University of Nebraska, which has 407 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02006576 being conducted?

This trial has 5 study locations across Alabama, California, Colorado, Nebraska, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Emphysema

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02006576's enrollment target sits among peer trials

118 15th of 25 higher than 11 of 25 other Emphysema trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Emphysema trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03821623 · 118 participants · Phase 2

    Nicotinamide Riboside for Treating Elevated Systolic Blood Pressure and Arterial Stiffness in Middle-aged and Older Adults

  • NCT04040959 · 118 participants · Phase 2

    Nicotinamide Riboside Supplementation for Treating Arterial Stiffness and Elevated Systolic Blood Pressure in Patients With Moderate to Severe CKD

  • NCT04696029 · 118 participants · Phase 2

    DFMO as Maintenance Therapy for Molecular High/Very High Risk and Relapsed Medulloblastoma

  • NCT05223192 · 118 participants · NA

    The Effects of Entrainment on Respiratory Stability and Cerebral Oxygenation in Preterm Infants

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT02006576, the US trial registry maintained by the National Library of Medicine. NCT02006576 (mid enrollment · multi site footprint · completed) retrieved and formatted by PlainTrial, see methodology.